H.C. Wainwright reiterates Alumis stock rating on TYK2 data
H.C. Wainwright reiterated a Buy rating and $15.00 price target on Alumis Inc (ALMS) after positive LATITUDE Atlas trial results for zaso. The stock trades at $6.85, down from its 52-week high. Analysts view the data favorably but note mixed reactions due to recent Phase 2b trial failures for Envudeucitinib.
How this was made
The 30-second read
Why it matters
The LATITUDE Atlas trial data provides the first robust efficacy signal, prompting analyst upgrades.
Market read
New clinical data could trigger a short‑term rally in ALMS as investors reassess the drug's potential.
What to watch
Potential regulatory delays and the mixed lupus trial results could temper upside.
Background
Alumis is a clinical‑stage biotech developing TYK2 inhibitors for dermatology and lupus.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $15 price target for Alumis after the LATITUDE Atlas trial showed significant efficacy improvements.
upward pressure as investors price in the improved efficacy signals
The trial results are new, material clinical data for a biotech; analysts have raised targets, suggesting near‑term buying interest.
Market effects
May boost sentiment in the dermatology and autoimmune biotech subsector.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond specialty pharma investors.
Counterpoint
The trial still leaves uncertainty about comparative efficacy versus Sotyktu, and cash burn remains high.
Key entities
- analystH.C. Wainwright
Reiterated Buy rating and set $15 price target.
- partnerTakeda
Launch of TYK2 inhibitor expected to create a new therapeutic category.
